A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Study Location:
Baltimore
Topic:
HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT02128217?term=a5327&rank=1
IRB#:
NA_00093365
Coordinator:
Anna Wimpelberg (Washington)
Ilene Wiggins, RN (Baltimore)
Enrollment:
Closed
Trial Period:
Completed
A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1 positive subjects will be enrolled and administered oral sofosbuvir (SOF) in combination with weight-based ribavirin (RBV).
Men and women > 18 years, HIV+ and currently on stable antiretroviral (ARV) medications or on for at least 8 weeks and be newly infected (within the last 6 months) or recently re-infected with hepatitis C.
Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org
Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu